2025年，沪市公司经营韧性与结构亮点进一步显现，在"质"与"量"的双重维度上，助力中国经济破浪前 行。数据显示，截至2月9日，271家沪市主板公司发布2025年业绩预告，其中168家预增、85家预计扭 亏。391家科创板公司以业绩预告或快报形式披露了2025年业绩情况，近六成公司预计净利润实现同比 增长，其中39家预计净利润同比倍增、51家预计扭亏为盈。 一幅稳增长、优结构的沪市公司全年发展图景徐徐展开。记者关注到，业绩突出的公司主要集中在有色 金属、电子等行业。有色金属受产品价格与产销量共同驱动，电子行业在AI需求带动下维持较快增 长。与此同时，一批龙头公司预计盈利规模仍处于高位，持续发挥沪市主板"压舱石"作用。 有色金属行业发展尽显韧性 2025年，在全球地缘政治摩擦多发和主要经济体降息预期的推动下，黄金的避险与货币属性愈加显现， 黄金价格屡创新高，直接增厚了拥有巨量黄金储备企业的利润。 有色行业规模以上企业工业增加值增长6.9%，高于全国规上工业增加值增速1.0个百分点，十种有色金 属产量首次突破8000万吨大关。规模以上企业实现利润总额5284.5亿元，同比增长25.6%，创下历史新 高。下游新兴产 ...

Core Viewpoint - The upcoming Chinese New Year holiday will lead to a 10-day market closure for A-shares, while Hong Kong stocks (H-shares) will continue trading, raising questions about whether H-shares can perform independently during this period. The recent adjustments in H-shares, combined with the surge in AI applications, prompt an analysis of whether the market has reached a correction point [1][3]. Market Trends - Historically, the Hang Seng Index has shown an 82% probability of rising in the three trading days before the Spring Festival, with a 40%-60% chance of increasing after the holiday. The correlation between H-shares and A-shares has strengthened, while the correlation with U.S. stocks has weakened, suggesting a potential for passive upward movement in H-shares [3]. Sector Performance - The Hang Seng Technology Index has seen significant performance metrics, with an average increase of 72.7% from Christmas to the Spring Festival. The average increase for the Hang Seng Index during the same period is 3.8% [4]. Investment Opportunities - The recent pullback in H-shares has made valuations more attractive, with expectations of a rebound. The Hang Seng Technology Index's price-to-earnings (P/E) ratio is currently at 24.5, which is below the historical average, indicating a favorable entry point for investors [7][8]. Innovation and Drug Development - Significant partnerships in the biotech sector, such as the collaboration between Innovent Biologics and Eli Lilly, highlight the potential for innovation in the pharmaceutical industry. This partnership includes a $350 million upfront payment and potential milestone payments totaling up to $8.5 billion [9]. Consumer Sector Dynamics - As the Spring Festival approaches, consumer activity is expected to rise, particularly in sectors like gold retail and hospitality. Government policies aimed at boosting consumption are likely to enhance market sentiment and drive growth in the consumer sector [11]. Dividend Strategies - In a low-interest-rate environment, dividend strategies are becoming increasingly attractive. The dividend yield for H-shares remains higher compared to A-shares, making them a compelling option for investors seeking stable returns [12][13]. Automotive Sector Growth - The automotive sector is poised for growth due to supportive policies and technological advancements in smart driving. The introduction of new policies for electric vehicle purchases is expected to stimulate demand, while advancements in autonomous driving technology present further opportunities [14][15].

Core Insights - The Chinese innovative drug industry is entering a new decade of development in 2025, with a significant increase in business development (BD) transactions, reaching a total value of $135.655 billion and 157 transactions, both setting historical records, indicating the growing global appeal of Chinese innovative drugs [1] - Milestone payments from previously established collaborations are beginning to materialize, providing cash flow relief for companies and marking substantial progress in global development [1] - However, potential risks associated with BD collaborations are emerging, including the premature termination of agreements and disputes leading to arbitration or litigation, signaling a need for caution in the industry [1] Industry Trends - The surge in BD transactions in 2025 is driven by the long-accumulated innovative potential of China's biopharmaceutical sector, with expectations for continued growth in cross-border transactions between China and the US/Europe [2] - The BD trend began in 2022, but many companies have not yet experienced the full lifecycle of BD transactions, leading to potential undisclosed issues in long-term performance [2] - The period from 2026 to 2028 may see an increase in BD disputes, as the industry transitions from rapid growth to a more regulated and mature phase [2] Financial Highlights - In May 2025, a record-breaking upfront payment of $12.5 billion was secured by a collaboration between Sangamo Therapeutics and Pfizer, with potential total payments reaching $48 billion [3] - In July 2025, China National Pharmaceutical Group announced a $300 million milestone payment from Merck for a collaboration on a PD-1/VEGF dual antibody [3] - In October 2025, a $250 million milestone payment was triggered for a collaboration between SystImmune and Bristol-Myers Squibb, marking the largest single milestone payment for an ADC asset disclosed in China [3] Payment Structures - The "upfront payment + milestone + sales royalty" model remains the dominant approach for Chinese companies in BD transactions, but only 22% of biopharmaceutical companies achieved milestone events by mid-2025, a decrease from previous years [4] - Among 128 transactions with at least one milestone node, 45% did not generate any revenue, highlighting the uncertainty of milestone payment realizations [4] - Increasing the proportion of upfront payments to secure immediate cash flow has become a consensus among companies to mitigate risks [4] Contractual Strategies - Companies are advised to enhance negotiation strategies by creating competitive environments and optimizing milestone payment terms to reduce ambiguity and disputes [5][6] - Specific, quantifiable conditions for milestone payments should be established to minimize subjective interpretations and risks of disputes [5] - The interrelation of contractual terms should be considered to avoid imbalances in rights and obligations, which could lead to significant disagreements during project execution [6] Legal Considerations - The potential for a wave of litigation in the BD sector is rising, driven by long-term contracts and various uncertainties affecting performance [7] - Companies often prioritize commercial negotiations to resolve disputes, but if unsuccessful, they must rely on the agreed dispute resolution mechanisms, emphasizing the importance of precise contract language [7][8] - Early identification of dispute trajectories and effective crisis management can significantly influence the outcome of legal proceedings [8] Future Outlook - As of January 2026, 17 BD transactions have occurred, totaling $133.61 billion, with significant projects continuing to emerge [9] - The ADC sector, small nucleic acid drugs, and in vivo CAR-T therapies are expected to be key areas for BD transactions in the next 1-2 years, with a shift in focus towards clinical data validation [10] - The industry is moving towards a more mature and regulated phase, with an emphasis on risk awareness and compliance as essential elements for successful cross-border BD initiatives [10]

Core Insights - The report from Southwest Securities indicates that first-line treatment for driver gene-negative NSCLC (non-small cell lung cancer) patients primarily relies on PD(L)-1 ± chemotherapy, with projected market sizes for immune drugs in this segment reaching approximately 7.5 billion yuan in China and 18 billion yuan in the U.S. by 2030 [1] Group 1: Market Overview - The driver gene-negative segment accounts for 31% of newly diagnosed NSCLC patients in both China and the U.S. [1] - The projected market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is estimated to be around 7.5 billion yuan in China and 18 billion yuan in the U.S. by 2030 [1] Group 2: Next-Generation Immunotherapy - Next-generation immunotherapy options for NSCLC are advancing, including bispecific antibodies and IO+ADC (immuno-oncology plus antibody-drug conjugates) [2] - Current PD(L)-1 drugs, such as Pembrolizumab and Atezolizumab, have established their clinical position but face limitations in long-term efficacy, particularly in patients with low PD-L1 expression [2] Group 3: Bispecific Antibody Treatment - Bispecific antibodies can bind to two antigens or epitopes, balancing safety and efficacy, with the approval of Ivorisumab in 2024 expected to stimulate interest in PD-(L)1/VEGF therapies [3] - The clinical data and technological pathways for bispecific antibodies are gaining recognition, with the potential for tri-specific antibodies to become a new trend in immuno-oncology treatment [3] Group 4: IO+ADC Treatment - ADCs combine cytotoxic drugs with monoclonal antibodies targeting tumors, offering precise delivery and effective treatment with lower toxicity [3] - Clinical results for TROP2 ADC combined with K-drug show comparable ORR and PFS data to K-drug plus chemotherapy, providing new solutions for patients intolerant to chemotherapy [3]

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced the completion of the first dosing of the EP-0210 monoclonal antibody injection in a Phase I clinical trial for treating inflammatory bowel disease, indicating progress in its drug development pipeline [1][3]. Group 1: Drug Overview - EP-0210 monoclonal antibody injection is a humanized IgG1 monoclonal antibody targeting TNF-like ligand 1A (TL1A), aimed at treating inflammatory bowel disease by blocking TL1A-mediated pro-inflammatory signaling pathways [1][2]. - Preclinical studies have shown that EP-0210 has a clear mechanism of action and significant efficacy in various inflammatory bowel disease models, demonstrating better target activity and efficacy compared to the foreign competitor RVT-3101 [2]. Group 2: Clinical Trial Details - The Phase I clinical trial for EP-0210 received formal approval from the National Medical Products Administration in January 2026, with the trial focusing on safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult participants [3]. - As of the announcement date, the first dosing in the single-dose administration phase of the trial has been completed [3].

Core Viewpoint - Yuan Dong Bio (688513) announced that its wholly-owned subsidiary Chengdu Youluo Biotechnology Co., Ltd. has initiated Phase I clinical trials for its monoclonal antibody EP-0210 injection, targeting inflammatory bowel disease, with the first patient dosing recently completed [1] Company Summary - EP-0210 is a humanized IgG1 monoclonal antibody that targets TNF-like ligand 1A (TL1A), aiming to treat inflammatory bowel disease by effectively binding to TL1A and blocking pro-inflammatory signaling pathways [1] - The development of TL1A antibody drugs is one of the most closely watched emerging targets in the field of inflammatory bowel disease, with no similar drugs currently available on the market globally [1] Industry Summary - The fastest global development progress for TL1A-targeting drugs is being made by Merck, Sanofi, and Roche/Pfizer, all of which have TL1A antibody drugs in Phase III clinical trials [1] - In China, companies such as 3SBio, ZhiXiang JinTai, and HuaShen ZhiYao have also entered Phase I clinical trials for similar TL1A-targeting drugs [1]

同泰大健康主题混合基金共经历4位基金经理的陆续管理，其现任基金经理为马毅和麦健沛，但可惜的 是，至今还没有一位在管理任期内实现正回报。 基金经理变动一览 中国经济网北京2月9日讯 2月4日，智通财经发布《2021年成立的基金还拿不回本？五成亏损 问题究竟 出在哪？》一文。文中称，2021年大量主动权益基金密集成立，但2021年那一批在牛市尾声发车的基金却 并没有集体扬眉吐气。智通财经记者以2021年成立并仍存续的667只主动权益基金为样本统计发现，截至最 新净值，仍有约362只成立以来收益为负，占比超过五成。其中86只基金自成立以来跌幅在30%以上，34只 的回撤更是超过40%。 根据天天基金网最新数据显示，成立于2021年4月8日的同泰大健康主题混合基金A/C，在截至2026年2 月6日的最新累计收益率为-56.45%和-57.28%，累计单位净值仅有0.4355元、0.4272元。 | 同泰大健康主题混合A(011002) | | | | --- | --- | --- | | 单位净值(2026-02-06) | 累计净值 | | | 0.4355 -1.34% | 0.4355 | | | 沂1月: ...

Group 1 - The Hong Kong stock market showed a strong opening on February 9, with the Hang Seng Index rising by 1.59%, the State-owned Enterprises Index increasing by 1.54%, and the Technology Index up by 1.9% [1] - The Hang Seng Biotechnology Index, focusing on innovative drugs, performed robustly, with the largest ETF tracking this index (159892) rising nearly 2% [1] - The innovative drug sector is expected to enter a profit realization acceleration phase by 2025, with companies like Innovent Biologics and Rongchang Biopharmaceuticals turning losses into profits, while companies like 3SBio are significantly increasing their performance [1] Group 2 - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product volume growth supported by medical insurance becoming the foundation for performance growth [1] - External collaborations, such as business development (BD) partnerships, are becoming important drivers for enhancing performance in the innovative drug sector [1] - The Hang Seng Medical ETF (159892) focuses on innovative drugs, CXO, and related industries, benefiting from the advantages of the Hong Kong Stock Exchange's 18A system, covering numerous innovative targets like BeiGene and Innovent Biologics, and is expected to continue its valuation recovery trend under catalysts like overseas expansion of innovative drugs and commercial insurance directories [1]

文章还表示，金元顺安医疗健康、同泰大健康主题、华泰柏瑞远见智选等，成立以来跌幅也都在50%以 上。 陈铭杰2016年6月加入金元顺安基金管理有限公司，历任专户投资部投资经理等。2023年10月27日起任基金 经理，管理经验尚不足3年。 张海东曾任中原农业保险股份有限公司资产管理部总经理、中国人民健康保险股份有限公司投资管理部处 长、渤海证券北京西外大街营业部担任交易部经理兼客服务部经理、大通证券北京营业部担任柜台主管、 分析师，2025年5月加入金元顺安基金管理有限公司，从2025年8月25日担任基金经理。 2025年4季度的前十大重仓股为三生国健、百利天恒、迪哲医药、百普赛斯（301080）、百济神州、艾力 斯、药明康德（603259）、恒瑞医药（600276）、迈威生物、博瑞医药。 中国经济网北京2月6日讯 2月4日，智通财经发布《2021年成立的基金还拿不回本？五成亏损 问题究竟出在 哪？》一文。文中称，2021年大量主动权益基金密集成立，时间一晃过去四年多，A股重新站在4000点上 方，但2021年那一批在牛市尾声发车的基金却并没有集体扬眉吐气。智通财经记者以2021年成立并仍存续 的667只主动权益 ...

金元顺安医疗健康混合C基金经理变动一览 | 起始期 | 截止期 | 基金经理 | 任职期间 | 任职回报 ② | | --- | --- | --- | --- | --- | | 2025-10-21 | ਦੇ ਹੇ | 臨絡森 张海东 | 108天 | -9.20% | | 2023-10-27 | 2025-10-20 | 臨密変 | 1年又359天 | -21.02% | | 2021-07-29 | 2023-10-26 | 贾丽杰 | 2年又89天 | -41.64% | 陈铭杰2016年6月加入金元顺安基金管理有限公司，历任专户投资部投资经理等。2023年10月27日起任 基金经理，管理经验尚不足3年。 张海东曾任中原农业保险股份有限公司资产管理部总经理、中国人民健康保险股份有限公司投资管理 部处长、渤海证券北京西外大街营业部担任交易部经理兼客服务部经理、大通证券北京营业部担任柜台主 管、分析师，2025年5月加入金元顺安基金管理有限公司，从2025年8月25日担任基金经理。 中国经济网北京2月6日讯 2月4日，智通财经发布《2021年成立的基金还拿不回本？五成亏损 问题究竟 出在哪？》一文。文 ...